VIDEO: Susvimo shows long-term efficacy in treating wet AMD

Issue: October 25, 2022

ByCarl D. Regillo, MD

ByAnthony DeFino

Fact checked byChristine Klimanskis, ELS

CHICAGO — In this Healio Video Perspective, Carl D. Regillo, MD, discusses 3-year follow-up data from the Archway study presented during Retina Subspecialty Day at the AAO meeting.

The Archway study investigated the Port Delivery System with ranibizumab, now called Susvimo (Genentech), for the treatment of wet age-related macular degeneration. It showed positive safety and efficacy results in patients who underwent 3 years of follow-up as well as those who underwent 1 year of follow-up in addition to previous intravitreal injections, according to Regillo.

Published by:

Sources/Disclosures

Collapse

Source:

Regillo C. Port Delivery System long-term portal extension data: Three-year follow-up from the phase 3 Archway study. Presented at: American Academy of Ophthalmology meeting; Sept. 30-Oct. 3, 2022; Chicago.

Disclosures: Regillo reports being a paid consultant for and receiving grant support from Genentech.

American Academy of Ophthalmology Meeting

Read more

VIDEO: Susvimo shows long-term efficacy in treating wet AMD

Related Content